Chemomab Therapeutics Ltd. (CMMB) NASDAQ
$0.78 0.01 (1.17%)
Market Cap: $1.43M
As of 03/28/24 04:00 PM EDT. Market closed.
Chemomab Therapeutics Ltd. (CMMB)
NASDAQ
$0.78
0.01 (1.17%)
Market Cap: $1.43M
As of 03/28/24 04:00 PM EDT. Market closed.
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple ... read more
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis). read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
OrbiMed Israel GP Ltd. | 10% Owner | Jan 03, 2023 | Sale | $3.58 | 336,900 | 1,207,759 | 2,311,798 | Jan 05, 2023, 04:49 PM |
Mor George Adi | Chief Scientific Officer | Jan 03, 2023 | Sale | $5.03 | 6,100 | 30,663 | 251,147 | Jan 05, 2023, 04:01 PM |
Mor George Adi | Chief Scientific Officer | Jan 03, 2023 | Sale | $5.03 | 7,700 | 38,706 | 317,075 | Jan 05, 2023, 04:01 PM |
Cohen Neil Harris | Director | Nov 16, 2022 | Sale | $2.00 | 2,409 | 4,818 | 10,000 | Nov 18, 2022, 07:53 AM |
Mor George Adi | Chief Scientific Officer | Nov 16, 2022 | Sale | $2.08 | 257,248 | 536,311 | 257,247 | Nov 17, 2022, 04:56 PM |
Mor George Adi | Chief Scientific Officer | Nov 16, 2022 | Sale | $2.08 | 324,775 | 677,091 | 324,775 | Nov 17, 2022, 04:56 PM |
Marvin Donald | Executive VP, CFO & COO | Mar 16, 2022 | Buy | $3.27 | 500 | 1,637 | 2,000 | Jun 21, 2022, 06:01 AM |
Maryles Joel Michael | Director | May 24, 2022 | Buy | $2.88 | 433 | 1,247 | 1,433 | May 25, 2022, 04:03 PM |
Cohen Neil Harris | Director | May 18, 2022 | Buy | $3.19 | 2,000 | 6,380 | 12,409 | May 19, 2022, 04:02 PM |
Maryles Joel Michael | Director | Mar 18, 2022 | Buy | $4.34 | 1,000 | 4,340 | 1,000 | Mar 21, 2022, 06:04 AM |
Marvin Donald | Executive VP, CFO & COO | Mar 14, 2022 | Buy | $4.04 | 1,250 | 5,045 | 1,500 | Mar 21, 2022, 06:02 AM |
Pfost Dale R | Chief Executive Officer | Mar 14, 2022 | Buy | $3.98 | 2,500 | 9,943 | 2,500 | Mar 15, 2022, 04:10 PM |
Cohen Neil Harris | Director | Mar 14, 2022 | Buy | $4.35 | 6,000 | 26,120 | 10,409 | Mar 15, 2022, 04:07 PM |
Darvish Nissim | Director | Mar 11, 2022 | Buy | $4.28 | 1,200 | 5,136 | 1,200 | Mar 14, 2022, 04:20 PM |
Cohen Neil Harris | Director | Dec 06, 2021 | Buy | $7.43 | 2,000 | 14,860 | 4,409 | Dec 08, 2021, 07:29 AM |
Cohen Neil Harris | Director | Mar 16, 2021 | Buy | $41.51 | 2,409 | 99,998 | 2,409 | Mar 26, 2021, 10:27 AM |
OrbiMed Israel GP Ltd. | 10% Owner | Mar 16, 2021 | Option Exercise | $17.35 | 288,170 | 4,999,750 | 2,578,174 | Mar 18, 2021, 09:59 PM |
Owner | Relationship | Date | Value($) |
OrbiMed Israel GP Ltd. | 10% Owner | 01/03/2023 | 1,207,759 |
Mor George Adi | Chief Scientific Officer | 01/03/2023 | 30,663 |
Mor George Adi | Chief Scientific Officer | 01/03/2023 | 38,706 |
Cohen Neil Harris | Director | 11/16/2022 | 4,818 |
Mor George Adi | Chief Scientific Officer | 11/16/2022 | 536,311 |
Mor George Adi | Chief Scientific Officer | 11/16/2022 | 677,091 |
Marvin Donald | Executive VP, CFO & COO | 03/16/2022 | 1,637 |
Maryles Joel Michael | Director | 05/24/2022 | 1,247 |
Cohen Neil Harris | Director | 05/18/2022 | 6,380 |
Maryles Joel Michael | Director | 03/18/2022 | 4,340 |
Marvin Donald | Executive VP, CFO & COO | 03/14/2022 | 5,045 |
Pfost Dale R | Chief Executive Officer | 03/14/2022 | 9,943 |
Cohen Neil Harris | Director | 03/14/2022 | 26,120 |
Darvish Nissim | Director | 03/11/2022 | 5,136 |
Cohen Neil Harris | Director | 12/06/2021 | 14,860 |
Cohen Neil Harris | Director | 03/16/2021 | 99,998 |
OrbiMed Israel GP Ltd. | 10% Owner | 03/16/2021 | 4,999,750 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 2,241,274 | 0.02% | No change | Other |
GEODE CAPITAL MANAGEMENT, LLC | 11,737 | 0% | No change | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View